A5049113823- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Monoclonal and Polyclonal Antibodies Research
- Liver Disease Diagnosis and Treatment
- Drug-Induced Hepatotoxicity and Protection
- Diagnosis and treatment of tuberculosis
- Celiac Disease Research and Management
- Gastrointestinal Tumor Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Diet, Metabolism, and Disease
- Tuberculosis Research and Epidemiology
- Diet and metabolism studies
- Inflammatory Myopathies and Dermatomyositis
- Peroxisome Proliferator-Activated Receptors
- Colorectal Cancer Surgical Treatments
- Adolescent and Pediatric Healthcare
- Liver physiology and pathology
- Autoimmune and Inflammatory Disorders Research
- Soft tissue tumor case studies
- Liver Diseases and Immunity
Université Libre de Bruxelles
2017-2025
Erasmus Hospital
2017-2025
Centre Hospitalier Universitaire Brugmann
2022
Centre Hospitalier Universitaire de Tivoli
2022
University of Mons
2022
GTx (United States)
2019
Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn's disease [CD]. Long-term real-world data are currently scarce CD patients previously exposed several biologics.This is an observational, national, retrospective multicentre study. Patients received intravenous UST ~6 mg/kg at baseline, with 90 mg subcutaneously thereafter every 8 weeks. Response and remission rates were assessed Weeks 8, 16, 52.Data from 152 analysed. All least one anti-TNFα...
Summary Background Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence support the effectiveness dose‐optimisation for ustekinumab nonresponse limited. Aim To assess dose escalation Methods This was multicentre retrospective cohort study. We included active disease who received standard‐dose intravenous induction and at least one subcutaneous 90 mg dose. All enrolled by either...
Abstract Background The natural course of Crohn's Disease (CD) can involve the development intra-abdominal strictures and fistulae (Montreal B2 B3 phenotypes, respectively). Yet, speed disease progression to these phenotypes may differ among patients. This study retrospectively analyses a large cohort CD patients with luminal phenotype at diagnosis B1) evaluates B2/B3 in tertiary centre Belgium. Methods A total 1,262 IBD were screened from 3000+ inflammatory bowel diseases (IBD) patient’s...
Abstract Background Randomized control studies have demonstrated the efficacy of subcutaneous infliximab (IFX SC) compared to placebo. However, real-life evidence remains scarce on impact this switch effectiveness, safety, pharmacokinetics (PK), and quality life in IBD management. Methods This is a 1 year longitudinal prospective single center cohort study (EC: P2021/570) comparing 2 groups: patients remaining IFX Intravenous (IV) (IV group) switching from IV SC (SC group). The population...
Abstract Background Since 1999, Biologics have become a cornerstone in the management of Crohn’s Disease (CD), enabling complete mucosal healing significant proportion patients, with measurable changes major outcomes large phase III/IV clinical trials. This holds true particularly when patients were exposed early at diagnosis to biologics, as reported recent PROFILE study. However, their real-world impact on long-term course disease remains uncertain. retrospective study aims characterize...
Abstract Background CD patients exhibit highly variable responses to biologics. While some achieve sustained remission with only one biologic over the course of their disease, other will require sequencing multiple biologics (“difficult-to-treat” patients) for optimal disease control. The aim this study was delineate profile treatment regimen biological exposed luminal disease. Methods Among diagnosed between 1999 and 2019 B1 phenotype at diagnosis, 203 who maintained maximum follow-up (FU,...
Hundreds of risk loci for immune mediated inflammatory and infectious diseases have been identified by genome-wide association studies (GWAS). Yet, what causal variants genes in underpin the observed associations remains poorly understood most. The identification colocalized cis-expression Quantitative Trait Loci (cis-eQTLs) is a promising way to identify candidate causative genes. catalogue cis-eQTLs system likely incomplete as many may be context-specific. We built large cohort 406 healthy...
Background Following STRIDE-II recommendations, the discovery of novel noninvasive biomarkers, beyond use C-reactive protein (CRP) and fecal calprotectin, remains a medical need to further improve monitoring patients with inflammatory bowel disease (IBD). This study aims evaluate potential serum lipopolysaccharide-binding (LBP) in IBD activity. Methods retrospective cross-sectional included 69 (43 Crohn’s 26 ulcerative colitis) 82 controls. Serum LBP levels were measured by ELISA. Clinical,...
Abstract Background and Aims Several factors have been reported to affect faecal calprotectin [FC] values, significant variation in FC concentrations has observed inflammatory bowel disease [IBD] patients. We aimed evaluate variability IBD patients, assess the robustness of a single stool punch. Methods This is single-centre observational case-control study. Disease activity was assessed using endoscopic clinical scores, as well C-reactive protein levels. Stool samples were collected twice...
Vedolizumab (VDZ) is effective as an induction and maintenance treatment for Crohn's disease ulcerative colitis, but, observed with antitumour necrosis factor-α (anti-TNFα) agents, some patients are nonetheless experiencing loss of response.The aim this study was to investigate the impact pharmacokinetics VDZ during on long-term response.This focused a single cohort 103 inflammatory bowel treated VDZ. trough levels (TLs) were measured by enzyme-linked immunosorbent assay (n=536 samples),...
Abstract Extracellular release of HMGB1 contributes to acetaminophen-induced liver injury. acts as a danger-associated molecular patterns during this toxic process but the mechanisms action and targeted cells are incompletely defined. Here we studied, in vitro , role amplifying hepatocyte necrosis process. Using cultured HepaRG cells, primary human hepatocytes selective chemical inhibitors evaluated toxicity. We confirmed that addition acetaminophen induced cell death release. showed...
Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss response (LOR) to IFX reported in up 10% 30% patients within first year treatment. Our objective was evaluate impact pharmacokinetics at induction on failure.This a longitudinal cohort study 269 with IBD treated single center. A total 2331 blood samples were prospectively collected from 2007 until March 2015 retrospective analysis clinical data. trough levels (TLs) measured by...
Although subcutaneous formulations of infliximab CT-P13 and vedolizumab are registered for treating moderate-to-severe inflammatory bowel disease [IBD], many questions on their use remain unanswered. We set up a multi-stakeholder initiative resulting in position statement.
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, VDZ or UST as a third-class biologic has not yet been described. Aims Methods: In this retrospective multicenter cohort study, we aimed to investigate CD. Results: Two-hundred four were included; 156/204 (76%) received second- therapy (group A); remaining 48/204 (24%) B). At week 16–22, 87/156...
Abstract Genome-wide association studies (GWAS) have identified hundreds of loci associated with Crohns disease (CD), however, as all complex diseases, deriving pathogenic mechanisms from these non-coding GWAS discoveries has been challenging. To complement and better define actionable biological targets, we analysed sequenced data more than 30,000 CD patients 80,000 population controls. We observe rare coding variants in established susceptibility genes well ten where variation directly...
Abstract Background Quality indicators are standardized, evidence-based measures of health care quality, categorised as structure (to assess the setting), process high-quality actions by healthcare professionals) or outcome (results undertaken professionals). Several quality indicator sets have been developed to standardise, measure and optimise IBD care. Our aim was develop validate a set in Belgium select subset with room for improvement that can be used implement improve clinical...
Background Very little is known about the impact of wash‐out period on pharmacokinetics a second‐line biologic. Objective The objective this article to explore two different periods vedolizumab and infliximab. Methods Patients switching from infliximab were retrospectively identified. population was divided into groups according period: <6 weeks or >6 weeks. Vedolizumab trough levels (TLs) determined correlated with clinical biological outcomes. Results A total 71 inflammatory bowel...
The loss of response to infliximab is a challenge for clinicians in the management inflammatory bowel disease (IBD). Mounting evidence suggests that therapeutic drug monitoring at induction may predict remission during maintenance. aim study was improve predictive models by exploring new peak and intermediate measurements induction.This prospective multicenter evaluating pharmacokinetics pioneer cohort 63 patients with IBD. Pharmacokinetics data including peak, intermediate, trough levels...
Extra-intestinal manifestations in inflammatory bowel diseases (IBD) are frequent and involve virtually all organs. Conversely, the clinical characteristics course of myopathies IBD remain poorly described mostly related to orbital myositis. Moreover, alternative therapeutic strategies non-responder patients corticosteroid therapy must still be clarified.A 33-year-old woman with a history unclassified colitis presented acute bilateral calf pain. On admission, her biological examinations were...
Abstract Background Therapeutic drug monitoring (TDM) is a diagnostic tool in the of anti-TNF therapies. Yet, benefit for TDM new biologics such as ustekinumab (USK) still controversial real-world experiences. Methods This monocentric retrospective study aims to correlate USK trough levels (TLs) with clinical and endoscopic data. All patients have given written consent Biobank (B2011/005). Endoscopic disease was defined quiescent absence lesions, mild presence few superficial ulcerations,...
Abstract Immune-mediated inflammatory diseases are characterized by variability in disease presentation and severity but studying it is a challenging task. Defining the limits of healthy immune system therefore prior step to capture conditions. The goal this study characterize global cell composition along with their influencing factors. Blood samples were collected from 2 independent cohorts respectively 389 (exploratory) 208 (replication) subjects. Twelve cells measured blood together...